January 30th 2023
Minimally invasive, novel system achieves significant pressure level reductions.
New genetic mutation behind childhood glaucoma identified
December 5th 2022Researchers found through DNA sequencing and confirmed in further testing that a genetic mutation in the THBS1 gene led to the development of severe childhood glaucoma. The discovery may improve disease screening and personalize treatments.
Read More
EP. 5: EyeCon 2022: Last chance to earn those end-of-year CME credits
November 10th 2022This December, the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide attendees with an end-of-year opportunity to meet their continuing medical education requirements. This activity has been approved for 12.50 AMA PRA Category 1 Credits™.
Read More
Nicox outlines future development, partnership plans for NX 470 in glaucoma
November 7th 2022The company said it plans to generate clinical data aiming to demonstrate the potential retinal benefits of NCX 470 in order to add significant therapeutic value to the product profile in glaucoma.
Read More
Private practice vs academics: What do young ophthalmologists need to know?
November 2nd 2022Nicole Bajic, MD, and Neel S. Vaidya, MD, MPH, share their insights from when they were at this crossroads. Learn more clinical pearls on topics like this and more at Real World Ophthalmology’s virtual conference, “Top 10 Things I Wish I Knew Sooner,” this Saturday, November 5.
Read More
EP. 4: EyeCon 2022: Mindset to explore new opportunities for your practice
October 21st 2022An interactive agenda at the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will foster an open exchange of ideas with fellow attendees from across the United States.
Read More
Real World Ophthalmology networking offers early-practice career advice
October 19th 2022Lisa M. Nijm, MD, JD, shares highlights from the Real World Ophthalmology 'After Dark' networking reception held at the American Academy of Ophthalmology annual meeting. The next Real World Ophthalmology meeting on November 5—which will be virtual—will cover important clinical, business, and personal growth areas for young ophthalmologists.
Read More
NIH backing first-in-class engineered mechanosensitive channel based gene therapy for glaucoma
October 9th 2022Nanoscope Technologies LLC announced this week it has received Direct Phase II SBIR grant from National Institutes of Health for developing an innovative approach to autonomously regulate pressure for treatment of Glaucoma in a gene-agnostic manner.
Read More